Biotech Values

[Shengli]

This is a slide from a recent CME program that i completed.

I find the ITPA genotype information very interesting .


New Factors Influencing Response
• Insulin resistance and hepatic steatosis decrease
response to treatment
– However, preliminary results using pioglitazone have
not demonstrated an enhanced antiviral response at
12 weeks1
• IL28B is perhaps the most useful new tool
• ITPA genotype may identify patients who are able to
tolerate high-dose RBV without significant anemia2• Vitamin D deficiency may impair response, and
supplementation may enhance it3

1. Harrison SA, et al. [Abstract 535]. Presented at: 2010 Digestive Disease Week; May 2-5, 2010; New Orleans, LA.
2. Thompson AJ, et al. [Abstract 2015]. Presented at: International Liver Congress 2010--45th Annual EASL Meeting;
April 14-18, 2010; Vienna, Austria.
3. Abu Mouch S, et al. [Abstract 55]. Presented at: International Liver Congress 2010--45th Annual EASL Meeting; April
14-18, 2010; Vienna, Austria.